U.S. Markets closed

CureVac’s COVID vaccine candidate 47% effective, stock tanks

·2 min read
CureVac’s COVID vaccine candidate 47% effective, stock tanks
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Curevac NV plunged more than 50% in the extended session Wednesday after the pharma company said its trial COVID-19 vaccine showed an efficacy of 47% against the illness.